Etravirine, sold under the brand name Intelence, is an antiretroviral medication used in the treatment of HIV-1 infection. It belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of the HIV virus. Unlike earlier NNRTIs, etravirine retains activity against certain strains of HIV that are resistant to other NNRTIs, making it an effective option for patients with drug-resistant HIV.
Etravirine is used as part of combination antiretroviral therapy and is typically prescribed for individuals with HIV-1 infection who have already been treated with other HIV medications.
Parent: Etravirine
As with all pharmaceutical products, impurities may develop in etravirine during its manufacturing, storage, or handling. Monitoring and controlling these impurities is essential to ensure the medication’s safety, efficacy, and quality.
Related Substances
These are chemically related compounds or byproducts formed during the synthesis of etravirine. Ensuring minimal levels of these substances helps maintain the drug’s purity and effectiveness.
Degradation Products
Etravirine may degrade when exposed to light, heat, or moisture, potentially impacting its safety and efficacy. Proper storage conditions are necessary to preserve its stability.
Residual Solvents
Trace amounts of solvents used during the manufacturing process may remain in the final product. Regulatory standards ensure these solvents are within permissible limits to minimize potential risks to patients.
Analytical Techniques for Monitoring Impurities
Techniques such as High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (LC-MS) are employed to detect and quantify impurities, ensuring etravirine meets stringent safety and quality standards.
Etravirine is used to treat HIV-1 infection as part of combination antiretroviral therapy. It is especially effective in individuals with HIV strains resistant to other NNRTIs.
Etravirine inhibits the reverse transcriptase enzyme, which HIV uses to convert its RNA into DNA, a critical step in the virus’s replication process. By blocking this enzyme, etravirine prevents the virus from multiplying and spreading.
Etravirine belongs to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of antiretroviral drugs, which are used to manage HIV infection.
No, etravirine is not a protease inhibitor. It is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which targets a different stage of the HIV replication process than protease inhibitors.
